Rocket Q2 2024 Earnings Report
Key Takeaways
Rocket Pharmaceuticals reported its Q2 2024 financial results, highlighting the advancement of its clinical pipeline, including RP-A501 and RP-A601 cardiac programs, and progress towards FDA approval for KRESLADI. The company's cash, cash equivalents, and investments totaled $278.8 million, expected to fund operations into 2026.
Continued advancement of Phase 2 pivotal study of RP-A501 for Danon Disease with ongoing patient enrollment.
Received orphan medicinal product designation from the European Commission for RP-A601 for PKP2 arrhythmogenic cardiomyopathy (ACM).
FDA review of limited additional Chemistry Manufacturing and Controls (CMC) information underway for KRESLADITM for the treatment of severe leukocyte adhesion deficiency-I (LAD-I).
Progressed Fanconi Anemia (FA) and Pyruvate Kinase Deficiency (PKD) programs through regulatory and clinical milestones.
Rocket
Rocket
Forward Guidance
Rocket Pharmaceuticals expects its cash, cash equivalents and investments of $278.8 million as of June 30, 2024, will be sufficient to fund its operations into 2026.